Subscribe to Newsletter

June 2020 Issue of The Medicine Maker

In this month’s issue, our cover feature examines how travel bans have affected the clinical trial landscape. Meanwhile, thought leaders from across the industry share their thoughts on the COVID-19 outbreak in In My View's Pandemic Diaries. In NextGen, we look into the benefits of 3D cell culture assays, and for Sitting Down With, we interview Paul Peter Tak, President and CEO at Kintai Therapeutics, on how research into the microbiome has accelerated in recent years.

Register to download
Register here to download any issue of The Medicine Maker for FREE.
Login
Forgot your password?
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Articles featured in this issue

 Discovery & Development Drug Discovery

Calming the Cytokine Storm

| Maryam Mahdi

How can salivary proteins derived from ticks help treat COVID-19?
Discovery & Development Drug Discovery

ADCs on the Rise

How will the ADC sector fair in 2020 and beyond?
Discovery & Development Drug Discovery

Preventing the Viral Trigger Pull

| Michael Schubert

A new vaccine protects against type 1 diabetes in animal models.
Discovery & Development Drug Discovery

Branching Out

| Maryam Mahdi

How can we reduce AI's energy consumption for improved drug discovery?
Business & Regulation Small Molecules

A Blueprint for Supply Chain Success

| Maryam Mahdi

Can the USA boost its manufacturing capacity for critical drugs?
Discovery & Development Drug Discovery

Trial Ready

The University of Oxford receives its first batch of AZD1222, a coronavirus vaccine candidate.
Discovery & Development COVID-19

The COVID-19 Curator

| Stephanie Vine

Your roundup of the key scientific studies and industry announcements emerging from the pandemic.
Business & Regulation Digital Technologies

The Digital Review

| Andrew Anderson

It’s time to address the bottlenecks that lie in quality assurance review and release – and digital systems can help.
Business & Regulation Business Practice

The Human Touch

| Sunil Jha

What measures can companies take to ensure the safety of their employees amid the COVID-19 outbreak?
Manufacture Supply Chain

Keeping the Show on the Road

| Kim Rice

The COVID-19 pandemic has put additional supply pressures on cold-chain products, such as those encapsulated by LNPs. How can delays be avoided?
Business & Regulation Supply Chain

Airplane Blues

| James Strachan

From patient recruitment to distributing products, we ask how clinical trials can weather the COVID-19 pandemic.
Manufacture COVID-19

Biopharma Banding Together

| Bill Jarvis

How has the COVID-19 pandemic changed the industry? And how can we respond faster next time?
Business & Regulation Business Practice

Access Not Denied

| Stephanie Vine

When developing countermeasures against COVID-19, resource-poor settings should not be forgotten.
Manufacture Technology and Equipment

Dimensions of Progress

| Maryam Mahdi

How far along is the pharmaceutical industry in its journey with 3D cell culture technologies?
Business & Regulation Business Practice

Making Money Through M&As

| George Chressanthis, Aditya Bhandari, Rashi Thaper

Do pharma mergers and acquisitions improve R&D productivity and increase shareholder value?
Discovery & Development Drug Discovery

Going with Your Gut Instinct

| Stephanie Vine

Sitting Down With… Paul Peter Tak, President and CEO at Kintai Therapeutics.

Other issues of 2020